PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Ariceum Therapeutics raise €25m in Series A co-led by HealthCap and EQT Life Sciences

Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has completed an oversubscribed €25 million Series A financing round.

Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures. Ipsen transferred assets, and all corresponding rights into the Company in late 2021.

The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, satoreotide, a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumours (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide will be used as a ‘theranostic’ for both the diagnosis and treatment of tumours expressing the SST2 receptor.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured